Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorprothixene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.57 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | HRH1 | P35367 | 4/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.97 |
| ▸ | HTR1A | P08908 | 2/20 | 0.97 |
| ▸ | HTR6 | P50406 | 2/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorprothixene SCHEMBL455759 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29857011 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL94236 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29357955 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29626798 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL24133 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL30383335 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL94235 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29462906 | 0.91 | LMNA (0.84) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL3491182 | 0.91 | LMNA (0.84) | LMNACYP3A4CYP2D6DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| CN-113521289-A | Application of 15 effective components of medicine in resisting virus infection | 中国科学院上海药物研究所 | 2021-10-22 | — | — | CN | claimed |
| US-20210041441-A1 | DISCOVERY OF NOVEL MOLECULES AND REPURPOSED DRUGS FOR RAS FAMILY GTPases | UNM RAINFOREST INNOVATIONS (US) | 2021-02-11 | — | — | US | claimed |
| EP-3233105-B1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LTD (GB) | 2020-09-30 | — | — | EP | claimed |
| US-20190321441-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | claimed |
| WO-2019173683-A1 | DISCOVERY OF NOVEL MOLECULES AND REPURPOSED DRUGS FOR RAS FAMILY GTPASES | STC. UNM (US) | 2019-09-12 | — | — | WO | claimed |
| US-20170348383-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-12-07 | — | — | US | claimed |
| EP-3233105-A1 | NOVEL COMBINATION AND USE | Helperby Therapeutics Limited (GB) | 2017-10-25 | — | — | EP | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| WO-2016097754-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2016-06-23 | — | — | WO | claimed |
| US-8524665-B2 | Use of secretin in treatments of disorders associated with the amygdala | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-09-03 | — | — | US | claimed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| US-20070185018-A1 | Use of secretin in treatments of disorders associated with the amygdala | THE MCLEAN HOSPITAL CORPORATION | 2007-08-09 | — | — | US | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| WO-2004100899-A2 | USE OF SECRETIN IN TREATMENTS OF DISORDERS ASSOCIATED WITH THE AMYGDALA | THE MCLEAN HOSPITAL CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| WO-2025072929-A1 | METHODS AND COMPOSITIONS OF TREATING AGE-RELATED CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-4894239-A | DRUG ADSORBED ON ION EXCHANGE RESIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-16 | — | — | US | disclosed |
| EP-0294103-A1 | A sustained-release preparation and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321441-A1 | NOVEL COMBINATION AND USE | TSLP, TLR5, TLR4 | DRD2 1673/4885DRD3 1794/4885HTR2A 1371/4885 |
| US-20170348383-A1 | NOVEL COMBINATION AND USE | TSLP, TLR5, TLR4 | DRD2 1673/4885DRD3 1794/4885HTR2A 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.